ERNA · Ernexa Therapeutics Inc
Price
Snapshot
50 fields · last close| Market Cap | $3.25M |
| P/E | — |
| Float | 1.15M |
| Beta | 2.79 |
| Volatility 30D | 95.7% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Micro cap |
| Macro sensitivity | Very High |
| Clavix score | 32.0 |
| Price | 1.77 |
| Change | −11.06% |
| Prev Close | 1.99 |
| Open | 1.98 |
| Day Low | 1.94 |
| Day High | 2.04 |
| Avg Vol | 0 |
| Avg $ Vol | $17.17K |
| 52W High | 47.25 |
| 52W Low | 1.84 |
| 52W Pos | −0.2% |
| From High | −96.25% |
| From Low | −3.74% |
| Max DD 1Y | −95.57% |
| Spread | 0.10% |
| Liquidity | Thin |
| SMA 20 | −15.92% |
| SMA 50 | −43.41% |
| SMA 200 | −74.45% |
| RSI (14) | 34.4 |
| Vol 90D | 101.5% |
| Vol 1Y | 146.6% |
| 1Y Range | 2–47 |
| Daily bars | 549 |
| Perf Week | +0.51% |
| Perf Month | −10.96% |
| Perf Quarter | −54.36% |
| Perf Half Y | −67.05% |
| Perf Year | −95.23% |
| Perf YTD | −93.90% |
| Prev Day | −11.06% |
| Clavix | F |
| Debt / Eq | 1.56 |
| Curr Ratio | 1.01 |
| Int Cover | -5.5× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 34 / 35 |
Clavix risk grade
regraded every trading dayERNA grades F, 32.0 of 100. Steadiest on Sector Resilience (58), most exposed on Price Stability (14, weak). 0 of the 3 weighted dimensions sit above the Biotechnology median. Ranks 34 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ERNA | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.79 | 0.49 |
| 30-day realized volatilityannualized, from daily closes | 95.7% | 46.0% |
| Max drawdown, past yearworst peak-to-trough fall | −95.6% | — |
| Typical daily movemedian absolute daily change | 4.17% | — |
| Days beyond ±3%of the last 252 sessions | 163 (65%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ERNA | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.79 | 0.49 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Low 54% of 35 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ERNA | |
|---|---|
| 1 week | +0.5% |
| 1 month | −11.0% |
| Year to date | −93.9% |
| 1 year | −95.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ERNA | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 11 May |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 26 · 2 |
| Directionarticles whose tone is improving vs worsening | 26 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 35 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ERNA | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openErnexa Therapeutics discussed its recent FDA engagement, the technology behind ERNA-101, and the development strategy supporting planned testing in people for the first time. The company presented ERNA-101 and its cell therapy platform as differentiated, but the supplied article provides no clinical data or specific FDA feedback.
Ernexa Therapeutics' drug candidate ERNA-101 was selected for a short oral presentation at a Nature Conferences meeting on next-generation cancer treatments, co-hosted by MD Anderson Cancer Center. Preclinical data showing the drug's potential to activate the tumor's surroundings in ovarian cancer and boost the effect of checkpoint inhibitors (drugs that help the immune system attack cancer) will be presented on October 6, 2026.
Ernexa Therapeutics announced in a CEO Corner piece that it has appointed Dr. Robert J. Spiegel, an experienced oncology drug developer, as the company moves its lead drug candidate ERNA-101 toward human clinical trials. The article references preclinical data in which ERNA-101, when combined with an anti-PD-1 immunotherapy (a type of drug that helps the immune system recognize and attack cancer cells), produced complete tumor clearance and 100% survival in the animal study.
Ernexa Therapeutics announced the appointment of Dr. Robert J. Spiegel, an experienced oncology drug developer, as the company sharpens its oncology focus and moves its lead candidate ERNA-101 toward clinical trials. The appointment follows preclinical data showing ERNA-101 achieved complete tumor clearance and 100% survival when combined with an anti-PD-1 immunotherapy.
Ernexa Therapeutics reported that its drug candidate ERNA-101 showed no safety problems across three studies required before testing in humans: a repeated-dose toxicology study in animals showed no tissue or blood abnormalities at any dose, and a single-dose study showed no acute immune-system overreaction. The company says these results move it toward filing an application to start human trials in the fourth quarter of 2026.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| VIVS | VivoSim Labs Inc | F | $2.56M | — | 1.67 | Compare |
| QTTB | Q32 Bio Inc. | F | $267.0M | 8.88 | 0.59 | Compare |
| CELC | Celcuity Inc. | C+ | $3.39B | — | 0.19 | Compare |
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.84 | Compare |
| ERAS | Erasca, Inc. | C | $5.21B | — | 0.66 | Compare |
| PTCT | PTC Therapeutics, Inc. | B | $5.76B | 8.34 | 0.49 | Compare |
| CGON | CG Oncology, Inc. | B- | $6.00B | — | 0.32 | Compare |
| IONS | Ionis Pharmaceuticals, Inc. | B- | $6.67B | — | 0.36 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.